Discover how neratinib, a second-generation targeted therapy, is proving effective against HER2-mutant breast cancers, offering new hope where traditional treatments sometimes fail.
Comprehensive guide to managing neratinib-induced diarrhea in HER2-positive breast cancer patients, including evidence-based strategies from the CONTROL trial.